Korean J Dermatol.  2010 Aug;48(8):672-677.

Phosphatidylcholine Formula for the Treatment of Lipoma

Affiliations
  • 1Department of Dermatology, Seoul Veterans Hospital, Seoul, Korea. apples28@freechal.com
  • 2Department of Dermatology, Anacli Dermatology Clinic, Seoul, Korea.
  • 3Department of Pathology, College of Medicine, Chung-Ang University, Seoul, Korea.

Abstract

BACKGROUND
Lipomas are benign neoplasms composed of mature fat cells. Current treatments are invasive and carry the risk of scarring. For this reason, phosphatidylcholine (PPC) formula has been widely used to treat areas of localized fat accumulation. However, there are few reports on injection lipolysis with injection of PPC formula.
OBJECTIVE
The purpose of this study was to investigate whether injection lipolysis with PPC formula is an effective therapeutic option for patients with lipoma.
METHODS
Twenty-two lipomas in 7 patients were included. Three sessions at intervals of 6 to 8 weeks were done. Sonographic measurements of lipoma size were repeated before each session. Any side-effects and the patients' satisfaction were noted. In one lipoma, histological changes after lipolysis were described.
RESULTS
After three sessions, a significant reduction in lipoma size of 47.4% was achieved. Histology showed a fibrosis with loss of adipocytes. Inflammation occurred in one case, so the patient was excluded from this study. Transient burning sensation and swelling at the injection site were the most common adverse effects. No severe side-effects or systemic reactions were observed.
CONCLUSION
Treatment of lipoma with PPC formula has the potential to be a patient-friendly and well-tolerated therapy that can achieve cosmetically pleasing treatment outcomes.

Keyword

Lipoma; Phosphatidylcholine formula

MeSH Terms

Adipocytes
Burns
Cicatrix
Fibrosis
Humans
Inflammation
Lipolysis
Lipoma
Phosphatidylcholines
Sensation
Phosphatidylcholines
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr